Bliss GVS Pharma Limited (BOM:506197)
India · Delayed Price · Currency is INR 218.00
+3.70 (1.73%)
At close: Feb 12, 2026
Bliss GVS Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 8,681 | 8,097 | 7,702 | 7,516 | 7,475 | 5,772 | |
Revenue Growth (YoY) | 7.19% | 5.13% | 2.48% | 0.55% | 29.49% | -16.26% |
Cost of Revenue | 4,279 | 4,305 | 4,007 | 4,136 | 4,031 | 3,375 |
Gross Profit | 4,402 | 3,792 | 3,695 | 3,380 | 3,444 | 2,397 |
Selling, General & Admin | 1,663 | 1,498 | 1,394 | 1,160 | 1,045 | 811.69 |
Other Operating Expenses | 1,333 | 1,027 | 795.34 | 1,047 | 1,212 | 502.63 |
Operating Expenses | 3,324 | 2,819 | 2,453 | 2,394 | 2,431 | 1,502 |
Operating Income | 1,078 | 972.66 | 1,242 | 986.49 | 1,013 | 894.47 |
Interest Expense | -113.07 | -77.5 | -60.51 | -98.64 | -36.93 | -43.01 |
Interest & Investment Income | 151.49 | 151.49 | 117.9 | 75.05 | 88.18 | 95.79 |
Currency Exchange Gain (Loss) | 160.06 | 160.06 | 111.35 | 77.69 | 200.57 | 78.86 |
Other Non Operating Income (Expenses) | 423.91 | 44.47 | 44.93 | 16.48 | 14.99 | 15.47 |
EBT Excluding Unusual Items | 1,701 | 1,251 | 1,456 | 1,057 | 1,280 | 1,042 |
Gain (Loss) on Sale of Investments | 1.93 | 1.93 | 1.72 | - | - | - |
Gain (Loss) on Sale of Assets | - | - | 2.86 | 3.65 | 0.68 | -0.31 |
Asset Writedown | - | - | - | - | -3.06 | - |
Other Unusual Items | -25.14 | - | -291.96 | - | -735.95 | - |
Pretax Income | 1,681 | 1,256 | 1,169 | 1,061 | 541.65 | 1,041 |
Income Tax Expense | 536.98 | 353.84 | 352.94 | 293.37 | 310.39 | 301.55 |
Earnings From Continuing Operations | 1,144 | 902.55 | 815.78 | 767.35 | 231.27 | 739.72 |
Net Income to Company | 1,144 | 902.55 | 815.78 | 767.35 | 231.27 | 739.72 |
Minority Interest in Earnings | -52.88 | -59.56 | -61.24 | -58.76 | -80.86 | -54.81 |
Net Income | 1,091 | 842.99 | 754.54 | 708.59 | 150.4 | 684.91 |
Net Income to Common | 1,091 | 842.99 | 754.54 | 708.59 | 150.4 | 684.91 |
Net Income Growth | 83.00% | 11.72% | 6.49% | 371.13% | -78.04% | -29.58% |
Shares Outstanding (Basic) | 106 | 105 | 104 | 104 | 103 | 103 |
Shares Outstanding (Diluted) | 107 | 106 | 106 | 105 | 105 | 105 |
Shares Change (YoY) | 1.06% | -0.04% | 0.56% | 0.26% | -0.26% | 2.26% |
EPS (Basic) | 10.33 | 8.02 | 7.23 | 6.83 | 1.46 | 6.64 |
EPS (Diluted) | 10.19 | 7.95 | 7.11 | 6.72 | 1.43 | 6.49 |
EPS Growth | 81.20% | 11.81% | 5.80% | 369.93% | -77.97% | -31.18% |
Free Cash Flow | - | 298.48 | 744.87 | -594.86 | 614.78 | 548.45 |
Free Cash Flow Per Share | - | 2.81 | 7.02 | -5.64 | 5.84 | 5.20 |
Dividend Per Share | - | 0.500 | 0.500 | 0.500 | 0.500 | 0.500 |
Gross Margin | 50.71% | 46.83% | 47.98% | 44.98% | 46.07% | 41.52% |
Operating Margin | 12.42% | 12.01% | 16.13% | 13.13% | 13.55% | 15.50% |
Profit Margin | 12.57% | 10.41% | 9.80% | 9.43% | 2.01% | 11.87% |
Free Cash Flow Margin | - | 3.69% | 9.67% | -7.92% | 8.22% | 9.50% |
EBITDA | 1,338 | 1,223 | 1,479 | 1,160 | 1,166 | 1,042 |
EBITDA Margin | 15.41% | 15.10% | 19.20% | 15.43% | 15.60% | 18.06% |
D&A For EBITDA | 259.79 | 249.85 | 236.6 | 173.54 | 152.62 | 147.88 |
EBIT | 1,078 | 972.66 | 1,242 | 986.49 | 1,013 | 894.47 |
EBIT Margin | 12.42% | 12.01% | 16.13% | 13.13% | 13.55% | 15.50% |
Effective Tax Rate | 31.95% | 28.16% | 30.20% | 27.66% | 57.30% | 28.96% |
Revenue as Reported | 9,425 | 8,462 | 7,990 | 7,694 | 7,789 | 5,974 |
Advertising Expenses | - | 72.5 | 84.27 | 61.7 | 48.05 | 18.17 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.